629 related articles for article (PubMed ID: 20535959)
1. [Proteasome inhibitor].
Yamamura M; Hirai T; Yamaguchi Y
Nihon Rinsho; 2010 Jun; 68(6):1079-84. PubMed ID: 20535959
[TBL] [Abstract][Full Text] [Related]
2. The proteasome: a novel target for anticancer therapy.
Montagut C; Rovira A; Albanell J
Clin Transl Oncol; 2006 May; 8(5):313-7. PubMed ID: 16760005
[TBL] [Abstract][Full Text] [Related]
3. The potential of proteasome inhibitors in cancer therapy.
Sterz J; von Metzler I; Hahne JC; Lamottke B; Rademacher J; Heider U; Terpos E; Sezer O
Expert Opin Investig Drugs; 2008 Jun; 17(6):879-95. PubMed ID: 18491989
[TBL] [Abstract][Full Text] [Related]
4. The proteasome as a potential target for novel anticancer drugs and chemosensitizers.
Landis-Piwowar KR; Milacic V; Chen D; Yang H; Zhao Y; Chan TH; Yan B; Dou QP
Drug Resist Updat; 2006 Dec; 9(6):263-73. PubMed ID: 17197231
[TBL] [Abstract][Full Text] [Related]
5. Synergistic interaction between the novel histone deacetylase inhibitor ST2782 and the proteasome inhibitor bortezomib in platinum-sensitive and resistant ovarian carcinoma cells.
Gatti L; Benedetti V; De Cesare M; Corna E; Cincinelli R; Zaffaroni N; Zunino F; Perego P
J Inorg Biochem; 2012 Aug; 113():94-101. PubMed ID: 22717676
[TBL] [Abstract][Full Text] [Related]
6. [Proteasome inhibitor bortezomib as an anticancer drug].
Yasui H; Hideshima T
Tanpakushitsu Kakusan Koso; 2006 Aug; 51(10 Suppl):1251-6. PubMed ID: 16922383
[No Abstract] [Full Text] [Related]
7. Novel proteasome inhibitors to overcome bortezomib resistance.
Ruschak AM; Slassi M; Kay LE; Schimmer AD
J Natl Cancer Inst; 2011 Jul; 103(13):1007-17. PubMed ID: 21606441
[TBL] [Abstract][Full Text] [Related]
8. Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies.
Ludwig H; Khayat D; Giaccone G; Facon T
Cancer; 2005 Nov; 104(9):1794-807. PubMed ID: 16178003
[TBL] [Abstract][Full Text] [Related]
9. Proteasome: an emerging target for cancer therapy.
Zavrski I; Jakob C; Schmid P; Krebbel H; Kaiser M; Fleissner C; Rosche M; Possinger K; Sezer O
Anticancer Drugs; 2005 Jun; 16(5):475-81. PubMed ID: 15846112
[TBL] [Abstract][Full Text] [Related]
10. Potential for proteasome inhibition in the treatment of cancer.
Adams J
Drug Discov Today; 2003 Apr; 8(7):307-15. PubMed ID: 12654543
[TBL] [Abstract][Full Text] [Related]
11. Targeting the proteasome pathway.
Tsukamoto S; Yokosawa H
Expert Opin Ther Targets; 2009 May; 13(5):605-21. PubMed ID: 19397479
[TBL] [Abstract][Full Text] [Related]
12. Bortezomib: a novel therapy approved for multiple myeloma.
Richardson PG; Anderson KC
Clin Adv Hematol Oncol; 2003 Oct; 1(10):596-600. PubMed ID: 16258456
[TBL] [Abstract][Full Text] [Related]
13. Sequencing bortezomib with chemotherapy and targeted agents.
Adjei AA
Clin Lung Cancer; 2005 Oct; 7 Suppl 2():S56-8. PubMed ID: 16250928
[TBL] [Abstract][Full Text] [Related]
14. Preclinical and clinical development of the proteasome inhibitor bortezomib in cancer treatment.
Montagut C; Rovira A; Mellado B; Gascon P; Ross JS; Albanell J
Drugs Today (Barc); 2005 May; 41(5):299-315. PubMed ID: 16082428
[TBL] [Abstract][Full Text] [Related]
15. Development of the proteasome inhibitor Velcade (Bortezomib).
Adams J; Kauffman M
Cancer Invest; 2004; 22(2):304-11. PubMed ID: 15199612
[TBL] [Abstract][Full Text] [Related]
16. Proteasome inhibition: a new approach for the treatment of malignancies.
Spano JP; Bay JO; Blay JY; Rixe O
Bull Cancer; 2005 Nov; 92(11):E61-6, 945-52. PubMed ID: 16316823
[TBL] [Abstract][Full Text] [Related]
17. Targeting the ubiquitin-proteasome pathway in cancer therapy.
Ishii Y; Waxman S; Germain D
Anticancer Agents Med Chem; 2007 May; 7(3):359-65. PubMed ID: 17504161
[TBL] [Abstract][Full Text] [Related]
18. Discovery, Development, and clinical applications of bortezomib.
Jung L; Holle L; Dalton WS
Oncology (Williston Park); 2004 Dec; 18(14 Suppl 11):4-13. PubMed ID: 15688597
[TBL] [Abstract][Full Text] [Related]
19. Ubiquitin and cancer: from molecular targets and mechanisms to the clinic -- AACR Special Conference.
Colland F
IDrugs; 2006 Mar; 9(3):179-81. PubMed ID: 16523381
[No Abstract] [Full Text] [Related]
20. Proteasome inhibition as a novel therapeutic target in human cancer.
Rajkumar SV; Richardson PG; Hideshima T; Anderson KC
J Clin Oncol; 2005 Jan; 23(3):630-9. PubMed ID: 15659509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
